L’Oréal and Walgreens back AI biomaterials start-up

photo: Shenzhen Boyin Biotechnology

Shenzhen Boyin Biotechnology

Chinese biotechnology company Shenzhen Boyin Biotechnology has raised US$27.5 million in Series A and A+ financing. The funding was co-led by L’Oréal’s BOLD investment fund, a fund established by Walgreens and Guangzhou Pharmaceutical, and Guangxin Fund.

Founded in 2021, Shenzhen Boyin combines synthetic biology and artificial intelligence to develop biomaterials for beauty, healthcare and nutrition applications. Its technologies include recombinant mussel adhesive protein and Colamin. The new capital will support research and development, production capacity and international commercialisation, reflecting growing investment in AI-enabled biotechnology for the cosmetics supply chain.